Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.
T-cells from the liver and lymph nodes show promising potential for future treatments of liver cancer, according to a new ...
About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.
Bristol Myers Squibb (BMS) has shared promising results from a late-stage study of its dual immunotherapy combination in ...
SAN DIEGO and SUZHOU, China - Adagene Inc. (NASDAQ: ADAG), a biotechnology firm with a market capitalization of $85 million ...
Medpage Today on MSN4d
Combination Slows Metastatic CRC Progression Better Than Single ImmunotherapyAn immunotherapy combination for advanced, highly mutated colorectal cancer (CRC) significantly slowed disease progression ...
Metastatic colorectal cancer with microsatellite instability-high or mismatch repair-deficient status represents a distinct ...
Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback